{"id":"W4281653962","doi":"10.1200/jco.2022.40.16_suppl.7551","title":"Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Oxaliplatin; Internal medicine; Tolerability; Gemcitabine; Neutropenia; Diffuse large B-cell lymphoma; Rituximab; Clinical endpoint; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002988419,0.001309755,0.001354465,0.0003318308,0.0002934909,0.001236773,0.0006382786,0.001201178,0.004237656],"category_scores_gemma":[0.002313097,0.0003948057,0.001399862,0.0003322541,0.0009305497,0.0008882551,0.000722979,0.003056629,0.0008042357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007590207,"about_ca_system_score_gemma":0.0008311147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005884169,"about_ca_topic_score_gemma":0.001736013,"domain_scores_codex":[0.9992172,0.0005516903,0.00002745722,0.00006970338,0.00005119695,0.00008266304],"domain_scores_gemma":[0.9985631,0.0004222721,0.0002987912,0.0001203349,0.0001014415,0.0004940712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9344555,0.009774356,0.005524158,0.0008704646,0.001756807,0.0002455408,0.000257181,0.002283246,0.009940441,0.0002342254,0.006324832,0.02833331],"study_design_scores_gemma":[0.7614355,0.2056115,0.01877685,0.0001347306,0.001965626,0.0004153149,0.0001578385,0.001196886,0.002520345,0.0005001636,0.007239592,0.00004565274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800305,0.005413806,0.000712151,0.0011679,0.000229978,0.00240252,0.004394707,0.0001307782,0.005517717],"genre_scores_gemma":[0.9820359,0.002272924,0.001084744,0.001752246,0.000284552,0.002100848,0.007636438,0.00005594137,0.002776274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004237656,"threshold_uncertainty_score":0.01580441,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05272054963104936,"score_gpt":0.428999063772115,"score_spread":0.3762785141410656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}